The estimated Net Worth of Robert E Conway is at least $271 Mille dollars as of 23 September 2021. Mr. Conway owns over 15,000 units of ARCA biopharma Inc stock worth over $120,000 and over the last 22 years he sold ABIO stock worth over $151,200. In addition, he makes $0 as Chairman of the Board at ARCA biopharma Inc.
Sign up
Mr. Conway ABIO stock SEC Form 4 insiders trading
Robert has made over 26 trades of the ARCA biopharma Inc stock since 2003, according to the Form 4 filled with the SEC. Most recently he sold 15,000 units of ABIO stock worth $151,200 on 23 September 2021.
The largest trade he's ever made was exercising 228,751 units of ARCA biopharma Inc stock on 8 October 2009 worth over $137,251. On average, Robert trades about 14,237 units every 120 days since 2003. As of 23 September 2021 he still owns at least 50,000 units of ARCA biopharma Inc stock.
You can see the complete history of Mr. Conway stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Robert Conway biography
Robert E. Conway has been appointed as Chairman of the Board of ARCA biopharma, Inc., with effect from June 9, 2014. He serves on the Audit and Compensation Committees of the Board of Directors. Mr. Conway has over 30 years of executive leadership experience in the pharmaceutical and biotechnology industries. Mr. Conway served as the Chief Executive Officer and member of the Board of Directors of Array BioPharma from 1999 to 2012. Array is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and inflammatory diseases. Prior to joining Array, Mr. Conway was the Chief Operating Officer and Executive Vice President of Hill Top Research, Inc., a clinical research services company, from 1996 to 1999. He also held various executive positions for Corning Inc. including Corporate Vice President and General Manager of Corning Hazleton, Inc., a contract research organization. Mr. Conway serves as the Chairman of Wall Family Enterprise, a leading library and education supplies company. He is on the Board of Directors of eResearch Technology, Inc. In addition, Mr. Conway is a member of the Strategic Advisory Committee of Genstar Capital, LLC.
How old is Robert Conway?
Robert Conway is 66, he's been the Chairman of the Board of ARCA biopharma Inc since 2014. There are 3 older and 9 younger executives at ARCA biopharma Inc. The oldest executive at ARCA biopharma Inc is Dr. Michael R. Bristow M.D., Ph.D., 76, who is the Co-Founder, Pres, CEO & Director.
What's Robert Conway's mailing address?
Robert's mailing address filed with the SEC is C/O ALPINE IMMUNE SCIENCES, INC., 188 EAST BLAINE STREET, SUITE 200, SEATTLE, WA, 98102.
Insiders trading at ARCA biopharma Inc
Over the last 16 years, insiders at ARCA biopharma Inc have traded over $9,048,465 worth of ARCA biopharma Inc stock and bought 3,605,825 units worth $6,507,167 . The most active insiders traders include Forest Baskett, Scott D Sandell e Anthony A. Jr. Florence. On average, ARCA biopharma Inc executives and independent directors trade stock every 54 days with the average trade being worth of $636,994. The most recent stock trade was executed by Henderson Group Plc Janus H... on 16 August 2024, trading 5,818 units of ABIO stock currently worth $17,047.
What does ARCA biopharma Inc do?
arca was founded on the belief that a precision medicine approach to drug development, tailoring medical treatment to the individual genetic characteristics of patients, can enable more effective therapies, improve patient outcomes and reduce healthcare costs. arca’s lead development program is intended to be a direct implementation of those ideas. gencaro™ (bucindolol hydrochloride) is being developed as a potential treatment for atrial fibrillation (af). arca has identified genetic variations in cardiac receptors that we believe may predict individual patient response to gencaro™, giving gencaro™ the potential to be the first genetically-targeted prevention treatment for af.
What does ARCA biopharma Inc's logo look like?
Complete history of Mr. Conway stock trades at ARCA biopharma Inc e Alpine Immune Sciences Inc
ARCA biopharma Inc executives and stock owners
ARCA biopharma Inc executives and other stock owners filed with the SEC include:
-
Michael Bristow,
President, Chief Executive Officer, Director -
Dr. Michael R. Bristow M.D., Ph.D.,
Co-Founder, Pres, CEO & Director -
Thomas A. Keuer,
Chief Operating Officer -
Christopher Ozeroff,
Senior Vice President, General Counsel, Secretary -
Christopher D. Ozeroff,
Sr. VP, Gen. Counsel & Sec. -
Raymond Woosley,
Director -
Daniel Mitchell,
Director -
Anders Hove,
Director -
Linda Grais,
Lead Independent Director -
Brian Selby,
Chief Accounting Officer, Principal Accounting Officer, Vice President - Finance -
Thomas Keuer,
Chief Operating Officer -
Robert Conway,
Chairman of the Board -
Dr. Debra Marshall FACC, M.D.,
Chief Medical Officer -
C. Jeffrey Dekker,
Chief Financial Officer -
Henderson Group Plc Janus H...,
-
Ravi Viswanathan,
10% owner -
Scott D Sandell,
10% owner -
David M Mott,
10% owner -
Anthony A. Jr. Florence,
10% owner -
Peter J Barris,
10% owner -
Healthcare Capital Partners...,
-
Peter W. Sonsini,
10% owner -
Jon Sakoda,
10% owner -
Joshua Makower,
10% owner -
Forest Baskett,
10% owner -
Equity Opportunities Fund I...,
-
Jean Francois Formela,
Director -
Kathryn E Falberg,
CFO and COO -
J William Freytag,
Director -
Mary K Pendergast,
Director -
Patrick M Wheeler,
acting Chief Financial Officer -
Riley Mccormack,
10% owner -
David George Lowe,
Director -
Burton E Sobel,
Director -
Venture Fund Vii L P Atlas,
10% owner -
Richard B Brewer,
Director -
John L Zabriskie,
Director -
Venture Partners Qualified ...,
10% owner -
Ted W Love,
Director -
Funds, Lp Ma Weaver Jacob F...,
-
Jacob Ma Weaver,
-
Fund, Lp Funicular,
-
C. Jeffrey Dekker,
Chief Financial Officer -
Fund, Lp Ma Weaver Jacob Fu...,
-
Funds, Lp Funicular,
10% owner -
James P Flynn,
Director